Cai Yimei, Wang Tingting
Department of Pharmacology & Physiology, Georgetown University Medical Center, Washington, D.C., USA.
Interdisciplinary Program in Neuroscience, Georgetown University Medical Center, Washington, D.C., USA.
J Physiol. 2024 Dec 20. doi: 10.1113/JP286751.
Alzheimer's disease (AD), the most common form of dementia among the elderly, affects numerous individuals worldwide. Despite advances in understanding the molecular underpinnings of AD pathology, effective treatments to prevent or cure the disease remain elusive. AD is characterized not only by pathological hallmarks such as amyloid plaques and neurofibrillary tangles but also by impairments in synaptic physiology, circuit activity and cognitive function. Synaptic homeostatic plasticity plays a vital role in maintaining the stability of synaptic and neural functions amid genetic and environmental disturbances. A key component of this regulation is presynaptic homeostatic potentiation, where increased presynaptic neurotransmitter release compensates for reduced postsynaptic glutamate receptor functionality, thereby stabilizing neuronal excitability. The role of presynaptic homeostatic plasticity in synapse stabilization in AD, however, remains unclear. Moreover, recent advances in transcriptomics have illuminated the complex roles of glial cells in regulating synaptic function in ageing brains and in the progression of neurodegenerative diseases. Yet, the impact of AD-related abnormalities in glial signalling on synaptic homeostatic plasticity has not been fully delineated. This review discusses recent findings on how glial dysregulation in AD affects presynaptic homeostatic plasticity. There is increasing evidence that disrupted glial signalling, particularly through aberrant histone acetylation and transcriptomic changes in glia, compromises this plasticity in AD. Notably, the sphingosine signalling pathway has been identified as being protective in stabilizing synaptic physiology through epigenetic and homeostatic mechanisms, presenting potential therapeutic targets for treating neurodegenerative disorders.
阿尔茨海默病(AD)是老年人中最常见的痴呆形式,影响着全球众多个体。尽管在理解AD病理学的分子基础方面取得了进展,但预防或治愈该疾病的有效治疗方法仍然难以捉摸。AD的特征不仅在于淀粉样斑块和神经原纤维缠结等病理特征,还在于突触生理学、神经回路活动和认知功能的损害。突触稳态可塑性在遗传和环境干扰下维持突触和神经功能的稳定性方面起着至关重要的作用。这种调节的一个关键组成部分是突触前稳态增强,其中突触前神经递质释放增加可补偿突触后谷氨酸受体功能的降低,从而稳定神经元兴奋性。然而,突触前稳态可塑性在AD突触稳定中的作用仍不清楚。此外,转录组学的最新进展揭示了胶质细胞在调节衰老大脑中的突触功能和神经退行性疾病进展中的复杂作用。然而,AD相关的胶质细胞信号异常对突触稳态可塑性的影响尚未完全阐明。本综述讨论了关于AD中胶质细胞失调如何影响突触前稳态可塑性的最新发现。越来越多的证据表明,胶质细胞信号的破坏,特别是通过胶质细胞中异常的组蛋白乙酰化和转录组变化,损害了AD中的这种可塑性。值得注意的是,鞘氨醇信号通路已被确定通过表观遗传和稳态机制对稳定突触生理学具有保护作用,为治疗神经退行性疾病提供了潜在的治疗靶点。